STOCK TITAN

[8-K] CNS Pharmaceuticals, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Form 4 filing overview: On 07/11/2025 Ralph Lauren Corporation (NYSE: RL) director Angela J. Ahrendts reported an automatic acquisition of 3.16 restricted stock units (RSUs) of Class A common stock. The RSUs were credited as dividend equivalents under the company’s 2019 Long-Term Stock Incentive Plan; no cash changed hands, and the stated price was $0.00.

Following the credit, Ahrendts’ direct holding rises marginally to 9,976.84 shares (including fractional RSUs). No derivative securities were involved, and there were no sales or open-market purchases.

Investment relevance: This is a routine, non-cash adjustment linked to the company’s dividend policy rather than an elective insider purchase. The fractional amount and automatic nature signal minimal financial impact and do not indicate a directional view on RL’s valuation or prospects.

Panoramica sulla presentazione del Modulo 4: Il 11/07/2025, Angela J. Ahrendts, direttrice di Ralph Lauren Corporation (NYSE: RL), ha comunicato un acquisto automatico di 3,16 unità azionarie vincolate (RSU) di azioni ordinarie di Classe A. Le RSU sono state accreditate come equivalenti dividendi nell'ambito del Piano Incentivi Azionari a Lungo Termine 2019 della società; non è avvenuto alcun scambio di denaro e il prezzo indicato era pari a 0,00$.

Dopo l'accredito, la partecipazione diretta di Ahrendts aumenta leggermente a 9.976,84 azioni (incluse le frazioni di RSU). Non sono stati coinvolti strumenti derivati, né sono state effettuate vendite o acquisti sul mercato aperto.

Rilevanza per l'investimento: Si tratta di un aggiustamento di routine, di tipo non monetario, legato alla politica dei dividendi della società e non di un acquisto volontario da parte di un insider. La quantità frazionaria e la natura automatica indicano un impatto finanziario minimo e non suggeriscono una posizione direzionale sul valore o sulle prospettive di RL.

Resumen de la presentación del Formulario 4: El 11/07/2025, Angela J. Ahrendts, directora de Ralph Lauren Corporation (NYSE: RL), reportó una adquisición automática de 3,16 unidades restringidas de acciones (RSU) de acciones ordinarias Clase A. Las RSU fueron acreditadas como equivalentes a dividendos bajo el Plan de Incentivos Accionarios a Largo Plazo 2019 de la compañía; no hubo intercambio de efectivo y el precio declarado fue de $0.00.

Tras el abono, la participación directa de Ahrendts aumenta marginalmente a 9,976.84 acciones (incluyendo fracciones de RSU). No se involucraron valores derivados, ni hubo ventas o compras en el mercado abierto.

Relevancia para la inversión: Se trata de un ajuste rutinario, sin efectivo, vinculado a la política de dividendos de la empresa y no a una compra voluntaria por parte de un insider. La cantidad fraccional y el carácter automático indican un impacto financiero mínimo y no reflejan una visión direccional sobre la valoración o perspectivas de RL.

Form 4 신고 개요: 2025년 7월 11일, Ralph Lauren Corporation(NYSE: RL) 이사 Angela J. Ahrendts가 자동 취득3.16 제한 주식 단위(RSU)의 Class A 보통주를 신고했습니다. 이 RSU는 회사의 2019년 장기 주식 인센티브 계획에 따른 배당금 등가로 적립되었으며, 현금 거래는 없었고 명시된 가격은 0.00달러였습니다.

적립 후 Ahrendts의 직접 보유 주식은 소수점 RSU를 포함하여 9,976.84주로 소폭 증가했습니다. 파생 증권은 포함되지 않았으며, 매도나 공개 시장 매수도 없었습니다.

투자 관련성: 이는 회사의 배당 정책과 관련된 일상적인 비현금 조정으로, 내부자의 자발적 매수와는 무관합니다. 소수점 단위와 자동성은 재무적 영향이 미미함을 나타내며 RL의 가치나 전망에 대한 방향성 신호가 아닙니다.

Présentation du dépôt du formulaire 4 : Le 11/07/2025, Angela J. Ahrendts, administratrice de Ralph Lauren Corporation (NYSE : RL), a déclaré une acquisition automatique de 3,16 unités d'actions restreintes (RSU) d'actions ordinaires de classe A. Les RSU ont été créditées en tant qu'équivalents dividendes dans le cadre du Plan d'Incitation à Long Terme en Actions 2019 de la société ; aucune transaction en espèces n'a eu lieu, et le prix indiqué était de 0,00 $.

Suite à ce crédit, la détention directe d’Ahrendts augmente légèrement pour atteindre 9 976,84 actions (y compris les fractions de RSU). Aucun titre dérivé n’a été impliqué, et il n’y a eu ni vente ni achat sur le marché libre.

Pertinence pour l’investissement : Il s’agit d’un ajustement de routine, sans échange d’argent, lié à la politique de dividendes de la société et non d’un achat volontaire d’initié. La quantité fractionnaire et le caractère automatique indiquent un impact financier minimal et ne reflètent pas une prise de position sur la valorisation ou les perspectives de RL.

Übersicht zur Form 4 Einreichung: Am 11.07.2025 meldete Angela J. Ahrendts, Direktorin der Ralph Lauren Corporation (NYSE: RL), eine automatische Erwerbung von 3,16 Restricted Stock Units (RSUs) der Klasse A Stammaktien. Die RSUs wurden als Dividendenäquivalente im Rahmen des langfristigen Aktienanreizplans 2019 des Unternehmens gutgeschrieben; es fand kein Bargeldtransfer statt, und der angegebene Preis betrug 0,00 $.

Nach der Gutschrift erhöht sich Ahrendts’ Direktbestand geringfügig auf 9.976,84 Aktien (einschließlich Bruchstücken von RSUs). Es waren keine Derivate beteiligt, und es gab keine Verkäufe oder Käufe am offenen Markt.

Investitionsrelevanz: Dies ist eine routinemäßige, nicht-bare Anpassung, die mit der Dividendenpolitik des Unternehmens zusammenhängt und keinen freiwilligen Insiderkauf darstellt. Die Bruchmenge und die automatische Natur deuten auf eine minimale finanzielle Auswirkung hin und zeigen keine richtungsweisende Einschätzung zur Bewertung oder den Aussichten von RL.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine fractional RSU credit; no directional signal.

The filing reflects only 3.16 dividend-equivalent RSUs automatically credited to Director Angela Ahrendts. Because the award is non-discretionary, carries no cost basis, and represents less than 0.01 % of the director’s holdings, it is immaterial to share count, insider sentiment, and near-term valuation. Investors can treat the event as administrative; no change to governance, liquidity, or insider positioning is implied.

Panoramica sulla presentazione del Modulo 4: Il 11/07/2025, Angela J. Ahrendts, direttrice di Ralph Lauren Corporation (NYSE: RL), ha comunicato un acquisto automatico di 3,16 unità azionarie vincolate (RSU) di azioni ordinarie di Classe A. Le RSU sono state accreditate come equivalenti dividendi nell'ambito del Piano Incentivi Azionari a Lungo Termine 2019 della società; non è avvenuto alcun scambio di denaro e il prezzo indicato era pari a 0,00$.

Dopo l'accredito, la partecipazione diretta di Ahrendts aumenta leggermente a 9.976,84 azioni (incluse le frazioni di RSU). Non sono stati coinvolti strumenti derivati, né sono state effettuate vendite o acquisti sul mercato aperto.

Rilevanza per l'investimento: Si tratta di un aggiustamento di routine, di tipo non monetario, legato alla politica dei dividendi della società e non di un acquisto volontario da parte di un insider. La quantità frazionaria e la natura automatica indicano un impatto finanziario minimo e non suggeriscono una posizione direzionale sul valore o sulle prospettive di RL.

Resumen de la presentación del Formulario 4: El 11/07/2025, Angela J. Ahrendts, directora de Ralph Lauren Corporation (NYSE: RL), reportó una adquisición automática de 3,16 unidades restringidas de acciones (RSU) de acciones ordinarias Clase A. Las RSU fueron acreditadas como equivalentes a dividendos bajo el Plan de Incentivos Accionarios a Largo Plazo 2019 de la compañía; no hubo intercambio de efectivo y el precio declarado fue de $0.00.

Tras el abono, la participación directa de Ahrendts aumenta marginalmente a 9,976.84 acciones (incluyendo fracciones de RSU). No se involucraron valores derivados, ni hubo ventas o compras en el mercado abierto.

Relevancia para la inversión: Se trata de un ajuste rutinario, sin efectivo, vinculado a la política de dividendos de la empresa y no a una compra voluntaria por parte de un insider. La cantidad fraccional y el carácter automático indican un impacto financiero mínimo y no reflejan una visión direccional sobre la valoración o perspectivas de RL.

Form 4 신고 개요: 2025년 7월 11일, Ralph Lauren Corporation(NYSE: RL) 이사 Angela J. Ahrendts가 자동 취득3.16 제한 주식 단위(RSU)의 Class A 보통주를 신고했습니다. 이 RSU는 회사의 2019년 장기 주식 인센티브 계획에 따른 배당금 등가로 적립되었으며, 현금 거래는 없었고 명시된 가격은 0.00달러였습니다.

적립 후 Ahrendts의 직접 보유 주식은 소수점 RSU를 포함하여 9,976.84주로 소폭 증가했습니다. 파생 증권은 포함되지 않았으며, 매도나 공개 시장 매수도 없었습니다.

투자 관련성: 이는 회사의 배당 정책과 관련된 일상적인 비현금 조정으로, 내부자의 자발적 매수와는 무관합니다. 소수점 단위와 자동성은 재무적 영향이 미미함을 나타내며 RL의 가치나 전망에 대한 방향성 신호가 아닙니다.

Présentation du dépôt du formulaire 4 : Le 11/07/2025, Angela J. Ahrendts, administratrice de Ralph Lauren Corporation (NYSE : RL), a déclaré une acquisition automatique de 3,16 unités d'actions restreintes (RSU) d'actions ordinaires de classe A. Les RSU ont été créditées en tant qu'équivalents dividendes dans le cadre du Plan d'Incitation à Long Terme en Actions 2019 de la société ; aucune transaction en espèces n'a eu lieu, et le prix indiqué était de 0,00 $.

Suite à ce crédit, la détention directe d’Ahrendts augmente légèrement pour atteindre 9 976,84 actions (y compris les fractions de RSU). Aucun titre dérivé n’a été impliqué, et il n’y a eu ni vente ni achat sur le marché libre.

Pertinence pour l’investissement : Il s’agit d’un ajustement de routine, sans échange d’argent, lié à la politique de dividendes de la société et non d’un achat volontaire d’initié. La quantité fractionnaire et le caractère automatique indiquent un impact financier minimal et ne reflètent pas une prise de position sur la valorisation ou les perspectives de RL.

Übersicht zur Form 4 Einreichung: Am 11.07.2025 meldete Angela J. Ahrendts, Direktorin der Ralph Lauren Corporation (NYSE: RL), eine automatische Erwerbung von 3,16 Restricted Stock Units (RSUs) der Klasse A Stammaktien. Die RSUs wurden als Dividendenäquivalente im Rahmen des langfristigen Aktienanreizplans 2019 des Unternehmens gutgeschrieben; es fand kein Bargeldtransfer statt, und der angegebene Preis betrug 0,00 $.

Nach der Gutschrift erhöht sich Ahrendts’ Direktbestand geringfügig auf 9.976,84 Aktien (einschließlich Bruchstücken von RSUs). Es waren keine Derivate beteiligt, und es gab keine Verkäufe oder Käufe am offenen Markt.

Investitionsrelevanz: Dies ist eine routinemäßige, nicht-bare Anpassung, die mit der Dividendenpolitik des Unternehmens zusammenhängt und keinen freiwilligen Insiderkauf darstellt. Die Bruchmenge und die automatische Natur deuten auf eine minimale finanzielle Auswirkung hin und zeigen keine richtungsweisende Einschätzung zur Bewertung oder den Aussichten von RL.

false 0001729427 0001729427 2025-07-15 2025-07-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 15, 2025

___________________________

 

CNS Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

___________________________

 

Nevada 001-39126 82-2318545

(State or other jurisdiction of

incorporation or organization)

(Commission File Number) (I.R.S. Employer Identification No.)

 

2100 West Loop South, Suite 900

Houston, Texas 77027

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (800) 946-9185

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

___________________________

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbols(s) Name of each exchange on which registered
Common stock, par value $0.001 per share CNSP The NASDAQ Stock Market LLC

 

 

   

 

 

Item 7.01.Regulation FD Disclosure.

 

On July 15, 2025, CNS Pharmaceuticals, Inc. (the “Company”) posted the investor presentation set forth in Exhibit 99.1 on its website.

 

The information contained in Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (“Securities Act”), unless specifically identified therein as being incorporated by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

No.   Description
99.1   Presentation dated July 2025
104  

Cover Page Interactive Data File (embedded within the Inline XBRL document)

  

 

 

 

 

 

 

 

 

 

 2 

 

 

Signature

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

CNS Pharmaceuticals, Inc.

 
       
       
  By: /s/ Chris Downs                          
    Chris Downs  
    Chief Financial Officer  
       
Dated: July 15, 2025      

 

 

 

 

 

 

 

 3 

FAQ

What did Angela Ahrendts report in the July 2025 Form 4 for RL?

She received 3.16 dividend-equivalent RSUs of Ralph Lauren Class A stock at a cost of $0.00.

How many Ralph Lauren shares does Angela Ahrendts now own?

After the transaction, she directly owns approximately 9,976.84 shares (including fractional RSUs).

Was this an open-market purchase or sale of RL stock?

No. It was an automatic RSU accrual tied to the company’s dividend, not an elective trade.

Does the filing indicate insider confidence in RL?

The fractional, non-cash nature of the award provides no meaningful insight into insider sentiment.

Were any derivative securities reported in this Form 4?

No derivative securities were acquired or disposed of in the reported period.
CNS Pharmaceuticals

NASDAQ:CNSP

CNSP Rankings

CNSP Latest News

CNSP Stock Data

5.13M
5.45M
0.44%
2.58%
17.91%
Biotechnology
Pharmaceutical Preparations
Link
United States
HOUSTON